The Role of Artificial Intelligence in Modern Drug Discovery and Development
Bibliographic record
Abstract
Drug research and discovery have been completely transformed by artificial intelligence (AI), which has improved the precision and efficiency of crucial procedures. Conventional medication development is frequently risky, expensive, and slow. From target discovery to clinical trial design, artificial intelligence (AI) can speed up several phases of drug development with machine learning (ML) and deep learning (DL) algorithms. Early on, the identification of new therapeutic targets is made possible by AI models' ability to forecast possible drug-target interactions. Additionally, by evaluating enormous chemical databases to determine which molecules are most likely to display the necessary biological activity, AI optimizes lead discovery by facilitating high-throughput screening of compounds. AI is also essential for drug repurposing, which is the process of finding new therapeutic uses for already-approved medications. AI can improve safety profiles by identifying trends in patient data that can be used to forecast unfavorable drug interactions. Furthermore, more precise in silico modeling is made possible by AI-driven simulations, which eliminates the need for expensive and time-consuming laboratory testing. AI-enabled clinical trials further improve result prediction, patient monitoring, and patient selection. AI can predict efficacy, find appropriate trial candidates, and expedite trial design by examining genomic data and electronic health information. The article explores how artificial intelligence (AI) is revolutionizing the entire drug development process, stressing both its present uses and its potential to change the pharmaceutical sector in the future and eventually result in the quicker and more affordable creation of new treatments.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.006 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.001 | 0.006 |
| Scholarly communication | 0.005 | 0.005 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.003 | 0.004 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".